Biotech Values

[flatlander_60048]

while I hope you are correct, however my pragmatic side says this market needs to see definitive proof that Sandoz is successful with sales at a decent margin. 2nd there is a lot of chatter that TEVA approval is right around the corner. I beleive that these two factors are likely to put a near term lid on MNTA.

I anticipate a short pop maybe followed by a slight pullback and then a long grind higher. Maybe the 3rd quarter NVS earnings call in October will ignite some excitement when we get a better feeling for market penetration. Every day without a TEVA approval represents another ring of the register for MNTA. I think the market will slowly do the math and realize that MNTA is making good money and paying off their share of development costs before share price appreciation takes off. I think MNTA news on copaxone and/or news on other high profile targets will help demonstrate the robustness of MNTA's platform.

That said I wouldn't mind being wrong and see a quick return to the mid 20's.

FL